These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 21948388)
1. Identification of a novel allosteric binding site in the CXCR2 chemokine receptor. de Kruijf P; Lim HD; Roumen L; Renjaän VA; Zhao J; Webb ML; Auld DS; Wijkmans JC; Zaman GJ; Smit MJ; de Graaf C; Leurs R Mol Pharmacol; 2011 Dec; 80(6):1108-18. PubMed ID: 21948388 [TBL] [Abstract][Full Text] [Related]
2. Nonpeptidergic allosteric antagonists differentially bind to the CXCR2 chemokine receptor. de Kruijf P; van Heteren J; Lim HD; Conti PG; van der Lee MM; Bosch L; Ho KK; Auld D; Ohlmeyer M; Smit MJ; Wijkmans JC; Zaman GJ; Smit MJ; Leurs R J Pharmacol Exp Ther; 2009 May; 329(2):783-90. PubMed ID: 19190236 [TBL] [Abstract][Full Text] [Related]
4. A common intracellular allosteric binding site for antagonists of the CXCR2 receptor. Salchow K; Bond ME; Evans SC; Press NJ; Charlton SJ; Hunt PA; Bradley ME Br J Pharmacol; 2010 Apr; 159(7):1429-39. PubMed ID: 20233217 [TBL] [Abstract][Full Text] [Related]
5. Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist. Gonsiorek W; Fan X; Hesk D; Fossetta J; Qiu H; Jakway J; Billah M; Dwyer M; Chao J; Deno G; Taveras A; Lundell DJ; Hipkin RW J Pharmacol Exp Ther; 2007 Aug; 322(2):477-85. PubMed ID: 17496166 [TBL] [Abstract][Full Text] [Related]
6. Interleukin 8, neutrophil-activating peptide-2 and GRO-alpha bind to and elicit cell activation via specific and different amino acid residues of CXCR2. Katancik JA; Sharma A; de Nardin E Cytokine; 2000 Oct; 12(10):1480-8. PubMed ID: 11023662 [TBL] [Abstract][Full Text] [Related]
7. Induction of CXCR2 receptor by peroxisome proliferator-activated receptor gamma in human macrophages. Rigamonti E; Fontaine C; Lefebvre B; Duhem C; Lefebvre P; Marx N; Staels B; Chinetti-Gbaguidi G Arterioscler Thromb Vasc Biol; 2008 May; 28(5):932-9. PubMed ID: 18292390 [TBL] [Abstract][Full Text] [Related]
8. Cloning and pharmacological characterization of CXCR1 and CXCR2 from Macaca fascicularis. Hipkin RW; Deno G; Fine J; Sun Y; Wilburn B; Fan X; Gonsiorek W; Wiekowski MT J Pharmacol Exp Ther; 2004 Jul; 310(1):291-300. PubMed ID: 15028780 [TBL] [Abstract][Full Text] [Related]
9. Interruption of G protein-coupling in CXCR2 does not alter ligand binding, but eliminates ligand-activation of GTPgamma35S binding, calcium mobilization, and chemotaxis. Yang W; Schraw WP; Mueller SG; Richmond A Biochemistry; 1997 Dec; 36(49):15193-200. PubMed ID: 9398246 [TBL] [Abstract][Full Text] [Related]
10. Identification of putative agouti-related protein(87-132)-melanocortin-4 receptor interactions by homology molecular modeling and validation using chimeric peptide ligands. Wilczynski A; Wang XS; Joseph CG; Xiang Z; Bauzo RM; Scott JW; Sorensen NB; Shaw AM; Millard WJ; Richards NG; Haskell-Luevano C J Med Chem; 2004 Apr; 47(9):2194-207. PubMed ID: 15084118 [TBL] [Abstract][Full Text] [Related]
11. An intracellular allosteric site for a specific class of antagonists of the CC chemokine G protein-coupled receptors CCR4 and CCR5. Andrews G; Jones C; Wreggett KA Mol Pharmacol; 2008 Mar; 73(3):855-67. PubMed ID: 18042736 [TBL] [Abstract][Full Text] [Related]
12. The collagen-breakdown product N-acetyl-Proline-Glycine-Proline (N-alpha-PGP) does not interact directly with human CXCR1 and CXCR2. de Kruijf P; Lim HD; Overbeek SA; Zaman GJ; Kraneveld AD; Folkerts G; Leurs R; Smit MJ Eur J Pharmacol; 2010 Sep; 643(1):29-33. PubMed ID: 20599927 [TBL] [Abstract][Full Text] [Related]
14. Discovery and mapping of an intracellular antagonist binding site at the chemokine receptor CCR2. Zweemer AJ; Bunnik J; Veenhuizen M; Miraglia F; Lenselink EB; Vilums M; de Vries H; Gibert A; Thiele S; Rosenkilde MM; IJzerman AP; Heitman LH Mol Pharmacol; 2014 Oct; 86(4):358-68. PubMed ID: 25024169 [TBL] [Abstract][Full Text] [Related]
15. Identification of overlapping but differential binding sites for the high-affinity CXCR3 antagonists NBI-74330 and VUF11211. Scholten DJ; Roumen L; Wijtmans M; Verkade-Vreeker MC; Custers H; Lai M; de Hooge D; Canals M; de Esch IJ; Smit MJ; de Graaf C; Leurs R Mol Pharmacol; 2014 Jan; 85(1):116-26. PubMed ID: 24174496 [TBL] [Abstract][Full Text] [Related]
16. Identification and characterization of a new interleukin-8 receptor in bovine species. Lahouassa H; Rainard P; Caraty A; Riollet C Mol Immunol; 2008 Feb; 45(4):1153-64. PubMed ID: 17727952 [TBL] [Abstract][Full Text] [Related]
17. SB265610 is an allosteric, inverse agonist at the human CXCR2 receptor. Bradley ME; Bond ME; Manini J; Brown Z; Charlton SJ Br J Pharmacol; 2009 Sep; 158(1):328-38. PubMed ID: 19422399 [TBL] [Abstract][Full Text] [Related]
18. Opioid and chemokine receptor heterodimers: arranged marriages or dangerous liaisons? Hébert TE Biochem J; 2008 Jun; 412(2):e7-9. PubMed ID: 18466114 [TBL] [Abstract][Full Text] [Related]
19. Chimeric, mutant orexin receptors show key interactions between orexin receptors, peptides and antagonists. Tran DT; Bonaventure P; Hack M; Mirzadegan T; Dvorak C; Letavic M; Carruthers N; Lovenberg T; Sutton SW Eur J Pharmacol; 2011 Sep; 667(1-3):120-8. PubMed ID: 21679703 [TBL] [Abstract][Full Text] [Related]
20. Intracellular trafficking of human CXCR1 and CXCR2: regulation by receptor domains and actin-related kinases. Matityahu E; Feniger-Barish R; Meshel T; Zaslaver A; Ben-Baruch A Eur J Immunol; 2002 Dec; 32(12):3525-35. PubMed ID: 12442335 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]